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Abstract
The neuroendocrine effects of leptin on metabolism hold promise to be translated into a
complementary therapy to traditional insulin therapy for diabetes and obesity. However,
injections of leptin can provoke inflammation. We tested the effects of leptin, produced in
the physiological adipocyte location, on metabolism in mouse models of genetic and dietary
obesity. We generated 3T3-L1 adipocytes constitutively secreting leptin and encapsulated
them in a poly-L-lysine membrane, which protects the cells from immune rejection.Ob/ob
mice (OB) were injected with capsules containing no cells (empty, OB[Emp]), adipocytes
(OB[3T3]), or adipocytes overexpressing leptin (OB[Lep]) into both visceral fat depots. Leptin
was found in the plasma of OB[Lep], but not OB[Emp] and OB[3T3] mice at the end of treatment
(72 days). The OB[Lep] and OB[3T3] mice have transiently suppressed appetite and weight
loss compared to OB[Emp]. Only OB[Lep] mice have greater brown fat mass, metabolic rate,
and reduced resistin plasma levels compared to OB[Emp]. Glucose tolerance was markedly
better in OB[Lep] vs. OB[Emp] and OB[3T3] mice as well as in wild type mice with high-fat diet-
induced obesity and insulin resistance treated with encapsulated leptin-producing adipo-
cytes. Our proof-of-principle study provides evidence of long-term improvement of glucose
tolerance with encapsulated adipocytes producing leptin.
Introduction
Obesity affects 150 million people worldwide and is characterized as pandemic disease [1, 2].
In North America, European Union, China, and other countries, obesity is considered to be a
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major risk factor for up to 70–90% of the adult cases of type II diabetes mellitus (T2DM) [1–3].
The treatment of diabetes with insulin induces accumulation of lipids in adipose, muscle, and
other peripheral tissues [4]. These effects reduce the efficacy of insulin therapy and are respon-
sible for the detrimental side effects increasing cardiovascular mortality in patients with diabe-
tes [5]. There is a critical need to develop therapies to treat obesity and diabetes that
simultaneously improve lipid and glucose homeostasis [4].
The adipokine leptin has been recently considered as a hormone candidate for managing
diabetes in the absence or presence of insulin diabetes therapy [6]. Leptin mediates its thera-
peutic effects on energy homeostasis through the hypothalamus and selected action on specific
neurons [7–14]. Leptin induces hypothalamic secretion of the appetite suppressing corticotro-
phin-releasing hormone [11]. Leptin stimulation releases sympathetic neurotransmitters, nor-
epinephrine and epinephrine, that increase activation of lipolysis and thermogenesis in white
adipose tissue (WAT) and brown adipose tissues (BAT) [14, 15]. Leptin works synergistically
with insulin to promote thermogenesis in WAT and increasing energy expenditure through
hypothalamic neurons [16]. Cumulatively, these effects, after leptin administration, reduce
obesity in mouse models of obesity and in human patients with homozygous Lepmutations or
congenital Lep deficiency [17–19]. Leptin’s simulation of the hypothalamus increases glucose
uptake in BAT, heart muscle, and skeletal muscle, but not WAT [12, 13]. Leptin and insulin
also synergize to increase glucose uptake in these tissues, in part via suppression of glucagon
[12]. These responses make leptin a promising biological target for a complementary therapy
to the traditional insulin treatments for diabetes and obesity.
A primary model for the development of leptin therapies is the ob/obmouse (Lepob, or ob),
a homozygous mutant in the leptin (Lep or ob gene) gene. In the absence of functioning leptin,
the ob/obmouse rapidly develops obesity and hyperglycemic conditions similar to T2DM [6,
20–22]. Reintroduction of leptin by injection of exogenous recombinant leptin, adenovirus
transduction restoring leptin expression in tissues, or transplantation of tissues producing lep-
tin attenuate weight gain, improve glucose tolerance, decrease appetite, and increase metabolic
rate in ob/obmice [6, 23–26]. However, these methods of leptin delivery cannot be directly
translated into therapies for humans. Leptin replacement therapy is necessary in patients with
homozygous Lepmutations or acquired leptin dysfunction that produces congenital and
acquired generalized lipodystrophy [17–19]. Treating these patients with recombinant leptin
through injections produces short lasting effects and requires repetitive doses. The supra-phys-
iological increase in leptin in the circulation followed by regular injections is associated with
serious side effects [27]. One study reports that endogenous production of leptin works better
than insulin injections [28]. However, there are limitations on how to safely increase endoge-
nous production of leptin. Increasing endogenous production by transduction using adenovi-
ruses carrying a functioning Lep gene [28, 29] or by the transplantation of tissues or cells
expressing functional leptin [26, 30, 31] pose risks of infection, immune rejection of the trans-
plant, or potential genetic viral contamination that could be hazardous to human health.
Transplantation models also require drugs to suppress the host’s immune system. To improve
transplant survival, Oosman et al, suspended leptin-producing intestinal cells in alginate beads;
however, this treatment also requires immunosuppression [26].
Recently, we employed a nanotechnology to develop a procedure of adipocyte microencap-
sulation [32] for the transplantation of genetically engineered cells into adipose tissue without
immune rejection [33]. The encapsulating poly-L-lysine generates a nanoporous membrane
that protects the encapsulated cells from the host’s immune system as well as allows small mol-
ecules, like hormones, to diffuse out of the capsule. Here we show that treatment with encapsu-
lated leptin-producing adipocytes improves glucose tolerance in genetic and diet-induced
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mouse models of obesity. Encapsulated leptin-producing adipocytes also reveal novel aspects
of leptin signaling including suppression of resistin in ob/obmice.
Results
Encapsulated adipocytes overexpressing Lep secrete leptin in vivo and
in vitro
The generated Lep (3T3Lep) preadipocytes and adipocytes expressed approximately 90,000
times greater levels of Lep compared to 3T3-L1 preadipocytes before (Fig 1A) and after differ-
entiation (Fig 1B). We validated adipogenesis using markers of preadipocytes, Pref1, and differ-
entiated adipocytes, Pparg [34]. A ratio of expressed Pref1 to Pparg was 98.4% lower in
differentiated vs. non-differentiated 3T3-L1 cells (P<0.02) (Fig 1C). Both 3T3-L1 and 3T3Lep
adipocytes differentiated for six days expressed similar levels of Pref1 (Fig 1D, n = 4, P<0.06).
Pparg expression was 33% lower than in differentiated 3T3Lep adipocytes (P<0.001) (Fig 1E).
To determine if Lep was translated and secreted, the supernatant media was analyzed for
secreted leptin in differentiated 3T3-L1 and 3T3Lepadipocytes. 3T3Lep, but not 3T3-L1, secreted
leptin into media (63.4 ± 13 ng/mL vs. 0.01 ± 0.01 ng/mL, n = 4, P<0.001) (Fig 1F). To test the
release of leptin from encapsulated preadipocytes, 3T3-L1 or 3T3Lep were encapsulated in poly-
L-lysine (described as [3T3-L1] and [3T3Lep], where brackets indicate encapsulation). The
detailed procedure and videoprotocol is described in [32]. After encapsulated cells were cul-
tured overnight, media was collected and analyzed for secreted leptin. Encapsulation did not
alter the leptin secretion by 3T3-L1 and 3T3Lep adipocytes, [3T3Lep], but not [3T3-L1], pro-
duced leptin (Fig 1G). The concentration of leptin produced by encapsulated adipocytes was
less than those of cultured preadipocytes (0.6 ng/mL vs. 63.4 ng/mL) due to the smaller number
of encapsulated cells in the well and shorter incubation time (Fig 1F vs. Fig 1G). Thus, encapsu-
lation permits leptin production and secretion from [3T3Lep] cells in vitro.
To test survival and production of leptin by [3T3Lep] adipocytes in vivo, we injected three
groups of ob/obmice with encapsulated acellular capsules (OB[Emp]), encapsulated 3T3-L1 pre-
adipocytes (OB[3T3]), and encapsulated 3T3Lep (OB[Lep]) in both visceral fat pads. Average
plasma leptin concentrations were measured 72 days post capsule injection in OB[Emp],
OB[3T3], and OB[Lep] to be 0 ± 0, 2.59 ± 4.5, and 122 ± 63 pg/mL, respectively (Fig 2A). Plasma
leptin levels were statistically greater in OB[Lep] than the other two groups (P<0.01). However,
OB[Lep] had lower plasma leptin levels when compared to WT mice fed a HF diet (7.4%,
0.22 ± 0.62 ng/mL vs. 1.66 ± 0.08 ng/mL) (Fig 2B). Therefore, encapsulated engineered adipo-
cytes engrafted in their physiological location in adipose tissues can increase plasma levels of
leptin for prolonged periods of time.
Leptin treatment by encapsulated adipocytes increases BAT and
metabolic rate
We recorded kinetics of food intake and weight gain for OB[Emp], OB[3T3], and OB[Lep] 14 days
before (S1A and S1B Fig) and 35 days after 21 days of treatment (Fig 2C and 2D) and weight at
the end of treatment (Fig 2E). Given the variability of individual metabolic responses in mice,
all food intake and weight data were normalized to the initial food intake (100%) or weight
(100%) in each mouse before treatment. The treatment with encapsulated adipocytes tran-
siently suppressed appetite in OB[Lep] compared to OB[Emp] mice. Food intake in OBLep group
was statistically lower than in OB[Emp] mice on day 9 post injection (Fig 2D). The suppression
of food intake coincided with transiently decreased weight in OB[Lep] mice compared to
OB[Emp] on days 2 and 7 post injection (Fig 2C). Treatment with encapsulated 3T3-L1 cells
Therapeutic Effects of Lep Producing Adipocytes
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also attenuated food intake and weight gain when compared to OB[Emp] mice (S1C and S1D
Fig). Both food intake and weight were not different between OB[Lep] and OB[3T3] groups.
Thus, treatment with encapsulated 3T3-L1 adipocytes with or without engineered secretion of
leptin from visceral location produced only minor and transient effects on appetite and weight.
To determine if these effects were due to an immune response, IL-6 was measured in plasma
and the VF of these mice. IL-6 was below detection levels in plasma and OB[Emp], OB[3T3], and
OB[Lep] had statistically the same levels of IL-6 in the VF (S2A Fig).
At the end of study wemeasured percent body fat measured by DEXA and weight of dissected
subcutaneous (SF), visceral (VF), and brown adipose fat (BAT) pads (Fig 3). Adipose tissues
were dissected as described in Yasmeen et al [35]. The percent of body fat measured by DEXA
(Fig 3A) as well as the weight of dissected SF (Fig 3B) and VF (Fig 3C), and liver weight (S1E
Fig) were not altered by any treatment in all mouse groups. In contrast, BATmass was increased
Fig 1. Engineered 3T3-L1 adipocytes express and constitutively secrete leptin. 3T3-L1 cells were stably
transduced to overexpress Lep (3T3Lep) (A, B) Lep expression in non-differentiated preadipocytes
(ND = non-differentiated) (A) and differentiated preadipocytes (D = differentiated) (B) is shown for 3T3-L1
(white bar) and 3T3Lep (black bar) (both n = 4, P<0.001). All gene expression was measured by qRT-PCR
and normalized to TATA box binding protein (TBP). (C) The ratio of Pref1 to Pparg expression non-
differentiated (ND, white bar) and differentiated (D, black bar) and 3T3-L1 (white bar) (n = 3, P<0.02). (D, E)
Pref1 (D) and Pparg (E) expression in differentiated (both n = 4) 3T3-L1 (white bar) and 3T3Lep (black bar,
P<0.001). (F) A mouse leptin ELISA was performed on media collected from confluent differentiated 3T3-L1
(white bar) and 3T3Lep (black bar) adipocytes that were incubated in this media for 48 hours (n = 4, P<0.001).
(G) Leptin concentration was measured by ELISA in media collected from a monolayer of encapsulated
3T3-L1 ([3T3-L1], white bar) and 3T3Lep ([3T3Lep], black bar) adipocytes cultured overnight. All data are
expressed as means ± SD (n = 4, P<0.001).
doi:10.1371/journal.pone.0153198.g001
Therapeutic Effects of Lep Producing Adipocytes
PLOS ONE | DOI:10.1371/journal.pone.0153198 April 7, 2016 4 / 18
in OB[Lep] mice. OB[Lep] had 175% greater BAT weight, when compared to OB[Emp] (Fig 3D).
This increase in BATmass was not associated with increased protein levels of UCP1 or PGC-1α
(S2B and S2D Fig). The significant increase in the BAT to VF ratio in OB[Lep] vs. OB[Emp] mice
groups (Fig 3E) was expected to increase metabolic rate in the leptin-treated group.
We tested the differences in metabolic parameters between OB[Emp], OB[3T3], and OB[Lep]
mouse groups using metabolic cages. Activity did not differ between groups (Fig 4A). OB[Lep]
had a greater VO2 (mL/kg/h) of 2000 ± 88 for dark cycle and 1822 ± 92 for light cycle than
OBEmp (1619 ± 113 and 1501 ± 122). The VO2 for OB
[Lep] mice was greater than OB[3T3] group
during the dark cycle (2000 ± 88 vs. 1875 ± 114) but not the light cycle (S3B Fig). OB[Lep]
group had a greater respiratory exchange ratio (RER) of 0.93 ± 0.01 for the dark cycle and
0.90 ± 0.01 for the light cycle than OBEmp (0.90 ± 0.01 and 0.87 ± 0.01) and OB[3T3]
Fig 2. Treatment with leptin-producing encapsulated adipocytes increases plasma leptin and
transiently influences food intake and weight.Ob/obmice (n = 7 per group) were injected with
encapsulated acellular capsules (OB[Emp]), encapsulated 3T3-L1 preadipocytes (OB[3T3]), and encapsulated
3T3Lep (OB[Lep]) in both visceral fat pads (total 0.6*106 adipocytes for each cell type). (A) Leptin
concentrations in plasma from OB[Emp] (n = 4), OB[3T3] (n = 4), and OB[Lep] (n = 7) mice. The leptin ELISA was
performed on non-hemolyzed plasma samples. All data are expressed as means ± SD. Significant
differences are shown with a black bar and determined by one-way ANOVA followed by Tukey’s post hoc test
(P<0.01). (B) Comparison of leptin concentrations in plasma from OB[Lep] (n = 7) andWTmice fed a high fat
(HF) diet for 60 days (n = 5). Leptin was analyzed by ELISA, (P<0.01, Student’s t-test). (C) Average food
intake kinetics in OB[Emp] (open circles, n = 6) and OB[Lep] (closed circles, n = 7) mice are shown as percent of
intake prior to injection. Asterisks show P<0.05, Student’s t-test. Data for OB[3T3] mice is in S1 Fig. (D)
Average weight kinetics in same groups of mice. Weight is shown as percent of weight prior to injection (g/g
prior to injection x 100). Asterisks show P<0.05, Student’s t-test. (E) Weights at sacrifice (72 days post-
treatment, mean ± SD) in same group of mice.
doi:10.1371/journal.pone.0153198.g002
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(0.91 ± 0.01 and 0.88 ± 0.01) for both the dark and light cycles (Fig 4C, 4E and S3C–S3E Fig)
suggesting that glucose utilization is higher in OB[Lep] compared to the other groups. The
OB[Lep] had a greater average metabolic rate of 9.89 ± 0.47 and 8.99 ± 0.46 kcal/h/kg for the
dark and light cycles when compared to 7.99 ± 0.57 and 7.36 ± 0.62 kcal/h/kg for OB[Emp]
(P<0.001) (Fig 4D and 4F). OB[Lep] had a higher metabolic rate than OB[3T3] for the dark cycle
(9.89 ± 0.47 vs 9.31 ± 0.66, P<0.005) but not the light cycle (8.99 ± 0.46 vs. 8.75 ± 0.60,
P<0.16) (S3D–S3F Fig).
Leptin treatment by encapsulated adipocytes improves glucose
tolerance and resistin
To access leptin’s role in glucose metabolism, we performed glucose tolerance and insulin tests
in all studied groups. The glucose tolerance test (GTT) responses in OB[Emp] and OB[3T3] mice
Fig 3. Treatment with leptin-producing encapsulated adipocytes increases BAT but not WAT weight.
(A) Average percent body fat for OB[Emp] (white bar, n = 5), OB[3T3] (gray bar, n = 5), and OB[Lep] (black bar,
n = 7) was measured using DEXA. Representative DEXA images are shown for each group. (B-D) Average
normalized weight of subcutaneous fat (SF, B), visceral (VF, C), and brown (BAT, D) to body weight in same
mouse groups. (E) The average ratio of BAT to VF in samemouse groups. All data are represented as
mean ± SD. Significant differences are shown by black bar and determined by one-way ANOVA followed by
Tukey’s test.
doi:10.1371/journal.pone.0153198.g003
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were similar (S4A and S4B Fig). OB[Lep] mice (78 ± 14%) were more sensitive to glucose than
OB[Emp] (100 ± 5%) and OB[3T3] (108 ± 20%) as measured by the AUC for GTT (Fig 5B). The
leptin treatment in OB[Lep] group resulted in significantly improved glucose tolerance compared
to OB[Emp] and OB[3T3] mice (Fig 5A, 5B and S4C, S4D Fig). Glucose levels during GTT test in
OB[Lep] mice were statistically lower than OB[3T3] mice (S4C Fig). Insulin tolerance tests (ITT)
were not different between OBEmp, OB[3T3], OB[Lep] groups (Fig 5C and S4B, S4D–S4F Fig).
We also considered other key factors influencing glucose metabolism that are regulated by
leptin, including insulin and glucagon [36]. Average insulin levels at sacrifice were 19.1 ± 5.7,
42.5 ± 28.9, 75.4 ± 43.9 ng/mL for OB[Emp], OB[3T3], and OB[Lep] mice, respectively (Fig 5C).
The insulin plasma concentration for OB[Lep] was 4 times greater than OB[Emp. However, the
individual insulin concentrations varied considerably within groups and the trend for lower
insulin in OB[Lep] vs. OB[Emp] was not statistically significant (Fig 5C). Glucagon levels of
1.11 ± 0.67, 0.86 ± 0.29, and 1.80 ± 0.87 ng/mL for OB[Emp], OB[3T3], and OB[Lep], respectively
were not statistically different (Fig 5E). We also examined resistin levels that is associated with
increased insulin resistance in adipocytes [37]. Resistin is decreased by 30% in the presence of
leptin (Fig 5E). Resistin concentration of 11.5 ± 3.1 ng/mL for OB[Lep] was less than the
16.5 ± 3.2 and 16.9 ± 2.0 ng/mL for OB[Emp] and OB[3T3], respectively.
Fig 4. Leptin increases metabolic rate and raises RER. (A-D) Metabolic measurements were performed in
OB[Emp] (white bar, n = 5) and OB[Lep] (black bar, n = 6) mouse groups in CLAMSmetabolic cages at 28 days
post injection. Metabolic data for OB[3T3] group are shown in S3 Fig. The average (mean ± SD) x, y, and z
activity (A), average VO2 (mL/kg/h) (B), respiratory exchange ratio (RER) (C), and average metabolic rate
(kcal/h/kg) (D) are shown for both the dark (D) and light (L) cycles. (E, F) Kinetic data for RER (E) and
metabolic rate (kcal/h/kg) (F) are shown as mean for each time point in OB[Emp] (open black circles) and
OB[Lep] (filled red circles) groups. Significant differences are shown by black bar and determined by one-way
ANOVA followed by Tukey’s test.
doi:10.1371/journal.pone.0153198.g004
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In previous studies [26], WTmice with a high-fat diet did not respond to treatment with lep-
tin produced by gut cells. To test efficacy of leptin produced by [3T3Lep] adipocytes in vivo, we
injected two groups of old WTmice with a high-fat diet-obesity and insulin resistance with
encapsulated acellular capsules (WT[Emp]), and encapsulated 3T3Lep (WT[Lep]) in both visceral
fat pads (Fig 5F). WT[Lep] mice had statistically lower AUC for glucose tolerance tests that was
30% less in WT[Lep] than inWT[Emp] (Fig 5F). Insulin tolerance tests were similar among all
studied groups (Fig 5G). Thus, constitutive leptin production in encapsulated adipocytes was
similarly efficient in improvement of glucose tolerance in mice with genetic or diet-induced obe-
sity and insulin-resistance.
Discussion
Two decades of research have established leptin as a key adipokine that regulates energy bal-
ance through the central nervous system and endocrine pathways [4, 36]. The leptin stimulated
Fig 5. Leptin improves glucose tolerance and reduces resistin. (A,B) Glucose tolerance tests (GTT) (A)
or insulin tolerance tests (ITT) (B) were performed in fasting overnight mice OB[Emp] (open circles, n = 5) and
OB[Lep] (filled circles, n = 5). GTT and ITT tests for OB[3T3] group are shown in S4 Fig. Average blood glucose
(mg/dL) concentrations are displayed for each time point. Asterisks indicate significant differences P<0.05,
Student’s t-test. The area under the curve (AUC) for each GTT was calculated using a trapezoidal
approximation and displayed as percent of the control OB[Emp] group (100%). (C-E) Plasma insulin (C),
glucagon (D), and resistin (E) concentrations were measured by ELISA in OB[Emp] (white bar, n = 4), OB[3T3]
(gray bar, n = 3), and OB[Lep] (black bar, n = 7). Statistical difference was examined by one-way ANOVA
followed by Tukey’s post hoc test. (F, G) WTmice with diet-induced obesity (Study 2) were injected with
encapsulated acellular capsules (WT[Emp]) and encapsulated 3T3Lep (WT[Lep]) in both visceral fat pads (total
0.6*106 adipocytes for each cell type). GTT (F) or ITT (G) were performed in fasting overnight miceWT[Emp]
(open circles, n = 3) andWT[Lep] (filled circles, n = 5). All data are represented as mean ± SD.
doi:10.1371/journal.pone.0153198.g005
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effects on the hypothalamus include: the regulation of appetite, an increase in metabolic rate,
an increase in lipolysis within WAT, and thermogenesis [4]. These effects of leptin may have
potential to be developed into a therapy for obesity. Recently, studies have shown that the
hypothalamic action of leptin on BAT and muscles can mediate lifesaving and antidiabetic
actions on both insulin-resistant and insulin-deficient rodents [38]. These studies provide a
rationale for the translation of leptin into a complementary therapy to insulin treatments for
type 1 and type 2 diabetes, which could improve the treatment of these diseases [36]. However,
the therapeutic application of leptin is limited by the detrimental effects of daily leptin injec-
tions [27]. Injection site reactions often include inflammation, erythema and ecchymoses [27].
Furthermore, the systemic spike of plasma leptin injections can lead to hypoglycemia, and
other complications [27]. Notably, hyperleptinemia has multiple deleterious effects [39, 40],
including epigenetic and transgenerational effects, that promote obesity in offspring [41]. In
2014, leptin injections were approved by the United States and other countries for the treat-
ment of congenital leptin deficiency and generalized lipodystrophy; however, the current meth-
ods of leptin delivery impede its use for the general population of patients with diabetes [41].
Physiologically, leptin is predominantly produced in circadian fashion in WAT [42]. In our
study, we mimic physiological leptin production by employing encapsulated adipocytes pro-
ducing leptin and by engrafting the capsules into a physiological location, the visceral fat. We
showed that a sub-physiological concentration of leptin produced by these engrafts can effec-
tively improve glucose tolerance in mice with genetic and diet-induced obesity.
The functions of leptin were established in ob/obmice with systemic leptin deficiency and
validated with the systemic injections of leptin or adenovirus producing leptin [25, 26, 28, 29].
The majority of systemic leptin effects (weight loss, thermogenesis, appetite suppression, and
improved glucose metabolism) were recapitulated by the direct stimulation of the hypothala-
mus with leptin. Implants of intestinal cells overexpressing leptin showed effective appetite and
weight loss in ob/obmice [26]. Some insight into the tissues-specific effects of leptin was gained
from these implantation studies. However, these implants failed to induce the same effects in
WT mice with high-fat diet-induced obesity and insulin-resistance [26]. However, the data
from this study need to be interpreted with caution because leptin production was induced
with a drug. Moreover, genetically different implants in this study were susceptible to rejection
by the host’s immune system, although they were introduced bound within an alginate polymer
[26]. Other leptin replacement therapies have attempted to investigate endogenous leptin pro-
duction by the transplantation of tissue [26, 30, 31]. However, these methods also induce an
immune response. Furthermore, the transplantation of tissues producing leptin is unlikely to
be a viable therapy for obese patients due to the health risks associated with transplantations.
Encapsulation of cells, using alginate-poly-L-lysine, may overcome the immune response. The
small size of the pores in the poly-L-lysine membrane excludes immunoglobulin influx [33,
43]. Encapsulated xenotransplants of porcine beta islets were able to survive and function in a
human patient for over 9.5 years without immune rejection [43]. Research suggests that ob/ob
mice have a weakened immune system [44, 45]. A weakened immune system may have allowed
encapsulated cells to survive in ob/obmice, but not in normal healthy WTmice. However, in a
previous study in C57BL/6 mice encapsulated cells were able to avoid immune rejection as
shown by foreign green fluorescent protein expression from the encapsulated cells weeks after
injection [33]. Nevertheless, the effect that poly-L-lysine encapsulation has on the immune sys-
tem and feasibility of using this encapsulation procedure should be fully elucidated in the
future because of the possibility that the capsules survived due to a weaker immune system in
ob/obmice.
Encapsulation of adipocytes in our study, allowed the effects of constitutively produced lep-
tin, within the visceral location, to be studied. In this pilot study, we introduced only 0.6 million
Therapeutic Effects of Lep Producing Adipocytes
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cells per visceral depot and achieved only 10% of level of leptin observed in obese WT mice.
Under these conditions, a limited leptin secretion from the capsules was not sufficient to reduce
appetite and weight loss for the duration of the study. However, it had a profound effect on glu-
cose metabolism, due to its systemic effects and effects in adipose tissue. This result also dem-
onstrates that encapsulated adipocytes were able to evade the immune system, survive, and
produce leptin for at least 72 days.
We attributed the transiently reduced weight and lower food intake, when compared to
empty capsule injected control, to a combination of factors. The first factor was a response to
the injections, since a decrease in food intake and weight was seen in all groups of mice during
the first couple days post treatment. The second factor was related to implanted 3T3-L1 adipo-
cytes. Food intake and weight of both OB[Lep] and OB[3T3] were significantly less than the empty
(acellular) capsule injected group on various days. This transient weight loss and food intake
reduction could be attributed to leptin as well as to the implantation of 3T3-L1 cells, because
similar effects were reported after cross-transplantation of adipose tissue from different depots
in ob/obmice [30]. Furthermore, it is possible that 3T3-L1 adipocytes could secrete some leptin
[46, 47]. Once 3T3-L1 adipocytes were implanted in the physiological VF environment, para-
crine signaling to the encapsulated 3T3-L1 adipocytes could have been sufficient to release mini-
mal amounts of leptin. The lack of the continual suppression of appetite and weight gain during
our study could be due to the sub-physiologic leptin concentrations in plasma from small
amount of encapsulated cells. It is also possible that leptin produced in the VF stimulates affer-
ent neural responses that are not involved in the regulation of appetite and weight, because neu-
ral effects on weight loss seem to be uncoupled from other leptin-dependent effects [48].
The primary outcome of leptin production in encapsulated adipocytes in our study was the
long-lasting improvement of glucose tolerance. This improvement was achieved by low, sub-
physiological circulating levels of leptin. Three different mechanisms were at work and could
be accounted for improved glucose uptake and utilization. We found: 1) increased BAT mass;
2) increased insulin; and 3) reduced resistin concentrations in plasma. Although WAT mass
and liver fat accumulation was not influenced by leptin in ob/obmice in our study, BAT mass
was markedly greater in OB[Lep] mice and associated with a higher basal metabolic rate. The
greater RER in OB[Lep] mice suggested the better glucose utilization that was demonstrated
using GTT test. Recent studies showed that activation of γ-aminobutyric (GABA) and pro-
opiomelanocorticitropin (POMC) neurons by leptin can induce BAT formation and function
to increase glucose utilization [4]. The stimulation of innervation can potentially lead to
improved secretion of insulin from pancreas, because studies in leptin-deficient β-cells suggest
only a moderate direct effect of leptin in these cells [49]. Insulin secretion increases after long-
term leptin administration [25]. Thus, both sub-physiological concentration of leptin from
physiological location and systematic injections of high leptin concentrations may be effective
in improving of insulin secretion.
Our study revealed also a new endocrine effect of leptin produced in VF location. OB[Lep]
mice secreted significantly less resistin compared to other treated groups. Resistin is an adipo-
kine that was identified in visceral adipocytes as a key cytokine inducing insulin resistance
[37]. Resistin deficiency in ob/obmice and DIO mice have been shown to improve glucose tol-
erance [50]. Resistin is widely implicated in the development of and progression of insulin
resistance in rodents and humans [37]. An antagonism between resistin and leptin secretion
from adipocytes has been previously demonstrated in vitro [51]. Here we provide evidence that
secretion of leptin from the small subset of encapsulated adipocytes is sufficient to mediate a
long term decrease in resistin concentrations in plasma. The reduction of resistin has more
beneficial outcome than the complete removal of resistin, because the complete removal of
resistin decreases metabolic rate [50].
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Our study shows that encapsulated adipocytes can produce leptin over 72 days. Although
the amount of capsules could be optimized, we showed that sub-physiological levels of leptin
produce an array of beneficial effects, notably long-term improved glucose tolerance. Leptin
treatment is considered to be ineffective in the general population of patients with obesity and/
or type 2 diabetes due to development of leptin resistance, hyperleptinemia, and insulin resis-
tance [52]. This effect is also present in WT mice with diet-induced obesity (DIO) [52]. Previ-
ous strategies to improve glucose tolerance in DIO mice were ineffective [26]. However, more
research is still needed to maximize the appetite suppressing and weight loss effects of encapsu-
lated cells. This may include the further engineering of adipocytes to produce greater amounts
of leptin or to develop other encapsulated leptin-producing cells, e.g. intestinal cells. In our
study leptin, produced by encapsulated adipocytes in physiological location, led to long lasting
improvement in glucose tolerance. Notably, this effect was achieved in severely obese old mice.
More research is needed to establish the therapeutic effects and biocompatibility of encapsu-
lated adipocytes to suggest that this delivery method offers advantages over standard delivery
methods including injections, adenovirus delivery, or transplantation of tissue. However,
encapsulation is a minimally invasive compared to surgical interventions and may be a cost-
effective procedure for delivery of leptin at a constant rate over a prolonged period of time
from months [33] to years [43] as well as to the termination of this procedure [33]. Our data
provide a proof of principle that the encapsulation of leptin-producing adipocytes could be
developed. Encapsulation is a feasible translational approach for the controlled delivery of
genes encoding adipokines into adipose tissue.
Materials and Methods
Chemicals and reagents
Unless otherwise noted, we purchased chemicals and reagents from Sigma-Aldrich (St. Louis,
MO) and cell culture media from Invitrogen (Carlsbad, CA).
Cell line engineering
To derive a leptin overexpressing 3T3-L1 preadipocyte cell line, we performed a stable transfec-
tion of 3T3-L1 (ATCC CL-173, obtained 8/2014 from the American Type Culture Collection,
Manassas, VA) using an untagged overexpressing leptin clone (GeneCopoeia, Rockville, MD,
catalog number EX-Mm03615-Lv67, CMV promoter, puromycin resistant) packaged in a
Lenti-Pac FIV Expression Packaging Kit (GeneCopoeia, Rockville, MD) according to manufac-
turer’s instructions. Briefly, lentiviral titers were produced using Lenti-Pac™ Lentiviral Packag-
ing Kits (GeneCopoeia, Rockville, MD). A total of 1.3–1.5 × 106 of the HEK293Ta Lentiviral
Packaging cells (GeneCopoeia, Rockville, MD) were plated in a 10-cm dish 2 days before trans-
fection in DMEM (10 mL), which was supplemented with 10% heat-inactivated fetal bovine
serum (FBS). Puromycin resistant lentiviral ORF leptin cDNA clone (2.5 μg; GeneCopoeia,
Rockville, MD), 5 μL Lenti-Pac FIV mix, and 15 μL of Endofectin–Lenti were diluted into
200 μL Opti-MEMI (Invitrogen, Grand Island, NY). The DNA–EndoFectin–Lenti complex
was incubated at room temperature for 15 min and then added directly to the cells. Cells were
incubated in a CO2 incubator at 37°C for 8–14 h. TiterBoost reagent (GeneCopoeia, Rockville,
MD, 0.2%) was added to the culture medium. Culture medium containing leptin pseudovirus
vector was collected 48 h post transfection after being centrifuged at 2000 rpm for 15 min. and
used for the transfection. Murine 3T3-L1 preadipocytes were grown in a 6-well plate until 80%
confluent. Then they were transfected with 1 mL of the vector-containing supernatant, 0.5 μL
Polybrene (Millipore, Billerica, MA) in 0.5mL 10% calf serum (CS). 24 h post transfection, cells
were replaced with a standard culture medium (DMEM containing 10% CS and 1% penicillin-
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streptomycin). At 90% confluence, cells were plated into 96-well plate with puromycin (1.0
mg/mL, Invitrogen, Grand Island, NY). The survived cells were plated in 96 well to achieve a
density of single cell per well. Stably transfected overexpressing leptin clones (3T3Lep) were
derived from a single cell and were tested for leptin mRNA expression by RT-PCR and leptin
release by ELISA (ALPCO, Salem, NH).
mRNA analysis
mRNA was purified from adipocytes or adipose tissue according to the manufacturer’s instruc-
tions (Qiagen, Germantown, MD) and quantified using 7900HT Fast Real-Time PCR System
and TaqMan fluorogenic detection system (Applied Biosystems, Grand Island, NY). The Lep
(Assay ID: Mm00434759_m1), Pref1 (Assay ID: Mm00494477_m1), and Pparg (Assay ID:
Mm00440945_m2) validated primers were also purchased from Applied Biosystems (Grand
Island, NY). Comparative real-time PCR was performed in triplicate, including no-template
controls. Expression was calculated using the comparative Ct method normalized to the TATA
box binding protein (TBP, Applied Biosystems, Grand Island, NY, Assay ID:
Mm00446973_m1).
Cell differentiation
All preadipocytes (3T3Lep and parent 3T3-L1 cells) were cultured in DMEMmedium contain-
ing 10% calf serum. Lipogenic differentiation medium contained 10% FBS, 10μg/mL insulin,
1μM dexamethasone, 0.5mM 3-isobutyl-1-methyl xanthine. Medium was replaced every 48
hours with DMEM containing 10% FBS, 10μg/mL insulin, and continued for 7 days.
Encapsulation
The phase microencapsulation technique has been performed as described [53]. The cell sus-
pension (1 x 106 cells/ml in 2% sodium alginate solution) was extruded through a 0.4-mm nee-
dle into a 100mM CaCl2 solution, using Encapsulation Unit (Nisco Engineering, AG,
Switzerland) at 5.4kV to form calcium alginate gel beads. Microbeads were solidified for 20
min, and then incubated with 0.05% (w/v) poly-L-lysine (MW 20,700) to form alginate-poly-
L-lysine membrane around the surface. The core was liquefied using 50mM sodium citrate.
Capsules0 properties were characterized before [53]. Encapsulated preadipocytes were main-
tained in culture under standard conditions for up to 30d.
Animal studies
All experimental protocols were approved by the Institutional Animal Care and Use Commit-
tee at the Ohio State University.
Mouse study one. Five week old ob/obmale mice (B6.Cg-Lep<ob>/J, The Jackson Labo-
ratory, Bar Harbor, ME, n = 21) were purchased, housed individually, and randomly assigned
into three groups and fed ad libitum a standard chow diet (irradiated 7912, Harlan Laborato-
ries, Indianapolis, IL) for 72 days. The following treatment groups were studied:
1. Control treatment group (OB[Emp]) (n = 5 at the conclusion of the study). Male ob/obmice
were injected with vehicle (0.3 mL of acellular (empty) capsules in 0.5 mL of sterile phos-
phate buffer (PBS) per visceral depot).
2. Encapsulated 3T3-L1 group (OB[3T3]) (n = 5 at the conclusion of the study). Male ob/ob
mice were injected with encapsulated 3T3-L1 preadipocytes (0.3106 3T3-L1 cells in 0.3 mL
of capsules in 0.5 mL of PBS per visceral depot).
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3. Encapsulated 3T3Lep group. (OB[Lep]) (n = 7 at the conclusion of the study). Male ob/ob
mice were injected with encapsulated 3T3Lep preadipocytes overexpressing leptin (0.3106
3T3Lep cells in 0.3mL of capsules in 0.5 mL of PBS per visceral depot).
All mice assigned to OB[Emp], OB[3T3], and OB[Lep] groups had similar weights before treat-
ments of 56.3, 56.8, and 58.0 g, respectively(P<0.80, ANOVA). After injection, mice continued
on a similar chow diet for 72 days and then sacrificed. Food intake and weight was monitored.
On day 28, mice were removed from standard housing and placed in metabolic cages for two
days, then returned to individual housing. Glucose tolerance tests (GTT) and insulin tolerance
tests (ITT) were performed three weeks prior to sacrifice. DEXA was performed on OB[Emp],
OB[3T3], and OB[Lep] just prior to sacrifice using the GE Lunar Prodigy (Fairfield, CT). Percent
body fat was measured using enCORE software (Fairfield, CT). On day 72, mice were anesthe-
tized using isoflurane (Piramal Healthcare Limited, Andhra Pradesh, India) and sacrificed.
Death was confirmed by removal of vital organs. Blood was collected by cardiac puncture into
EDTA-containing tubes. Plasma was prepared by centrifugation. One whole subcutaneous
(inguinal, lower back) and visceral fat (perigonadal/epididymal) pads were dissected as shown
in [35] and homogenized in RIPA buffer with protease inhibitors.
Mouse study two. Eight C57BL/6 (WT) five week old male mice (The Jackson Laboratory,
Bar Harbor, ME) were fed a high-fat (HF) diet (45% kcal from fat, D12451, Research Diets
Inc., New Brunswick, NJ) for 218 days. Mice were housed together in two groups and food
intake and weight was recorded. Treatments were:
1. Control treatment group (WTEmp) (n = 3). Body weight at the beginning of study was 56.3
±2.9g. WT male mice were injected with vehicle (0.3 mL of acellular (empty) capsules in 0.5
mL sterile phosphate buffer (PBS) per visceral depot);
2. [3T3Lep] treatment group (WT[Lep]) (n = 5). Body weight at the beginning of study was 58.0
±3.3g WT male mice were injected with encapsulated 3T3Lep preadipocytes overexpressing
leptin (0.3106 3T3Lep cells in 0.3 mL of capsules in 0.5 mL of PBS per visceral depot).
After injection, mice continued on the same HF chow diet for 70 days and glucose and insu-
lin tolerance tests were performed. Prior to sacrifice, the three heaviest mice in the WT[Lep]
group died before the end of study and tissues were unable to be harvested prior to
degradation.
Glucose and insulin tolerance tests
For GTT and ITT, mice were fasted overnight. They were injected with a single intraperitoneal
glucose dose (0.001g glucose/g body weight) for GTT. Blood was obtained from mouse tails.
Blood glucose was measured by One Touch Ultra glucometer (LifeScan). For mice were fasted
overnight. Mice allowed recovered for at least one week, then ITT test was performed using a
single intraperitoneal insulin dose (1mU of insulin/g body weight). Blood glucose was
measured.
Western blot analysis
Aliquots from fat pad homogenates were used for protein (Bicinchoninic Acid Kit, Thermo
Scientific, Waltham, MA) measurements, and Western blots. For Western blot analyses, tissue
lysates were separated on 10% acrylamide gel under reducing conditions. After transfer to poly-
vinylidene fluoride membranes (Immobilon-P, Millipore, Billerica, MA), the membranes were
stained with primary antibodies against UCP1 (Abcam, Cambridge, MA), PGC-1α (Abcam,
Cambridge, MA), and β-actin (Cell Signaling, Danvers, MA) and then detected with the
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appropriate secondary antibody (LI-COR, Lincoln, NE). Proteins were analyzed using an
Odyssey Infrared Imaging System (LI-COR, Lincoln, NE). Images were quantified by ImageJ
software.
Metabolic measurements
In study one, metabolic parameters in the treated mice were measured by indirect calorimetry
(CLAMS, Columbus Instruments, Columbus, OH) at ambient temperature (22°C) with 12
hours light/dark cycles. Animals were fed the same diet and water provided ad libitum. Mice
were placed individually and allowed to acclimate to the metabolic cages. O2 consumption,
CO2 production, energy expenditure, and locomotor activity were measured for 24 hours.
Based on these data, respiratory quotient or exchange ratio (CO2/O2) and Δ heat values were
calculated by CLAMS.
ELISA assays
Leptin (mouse/rat) ELISA (ALPCO, Salem, NH) was performed on media samples and plasma
samples. 3T3-L1 and 3T3Lep were differentiated as described (n = 5). 2 mL of fresh media was
added to the differentiated cells and incubated for 48 h. Media samples were collected and lep-
tin (mouse/rat) ELISA (ALPCO, Salem, NH) was performed according to manufacturer’s
instructions. 3T3-L1 and 3T3Lep were encapsulated in poly-L-lysine as described. 200μL of
encapsulated 3T3-L1 ([3T3-L1]) or encapsulated 3T3Lep ([3T3Lep]) were added to 2mL of fresh
cell culture medium (DMEMmedium containing 10% CS). After 24 h incubation, media sam-
ples were taken, centrifuged, and filtered to remove capsules. Leptin (mouse/rat) concentra-
tions in the media were measured by ELISA (ALPCO, Salem, NH) according to the
manufacturer’s instruction. Insulin concentration in plasma (diluted 1 to 20) was determined
using the Rat/Mouse Insulin ELISA Kit (EMDMillipore Corporation, St. Charles, MO). Resis-
tin concentration in plasma (diluted 1 to 50) was determined using Quantikine ELISA Mouse
Resistin Immunoassay (R&D Systems, INC., Minneapolis, MN). Hemolyzed plasma samples
were excluded from measurements according to manufacturers’ recommendations.
IL-6 concentration in plasma (diluted 1 to 5) and in VF (30μg of protein per sample) was
determined using Quantikine ELISA Mouse IL-6 Immunoassay (R&D Systems, INC., Minne-
apolis, MN). Hemolyzed plasma samples were excluded from measurements according to
manufacturers’ recommendations.
Statistical analysis
Data are shown as mean±SD of experiments that were performed at least with n = 3 for clone
characterization in vitro and n = 5 in vivo unless otherwise noted. Group comparisons of three
or more independent groups were performed using one-way ANOVA followed by Tukey’s
post hoc test unless otherwise indicated. For comparisons of two independent groups, the Stu-
dent’s t-test was used unless otherwise indicated. Significance level was set at an alpha = 0.05
unless otherwise noted.
Supporting Information
S1 Fig. Kinetics of food consumption and weight, liver weight, and UCP1 expression in
BAT.Ob/obmice (n = 7 per group) were injected with encapsulated acellular capsules
(OB[Emp]), encapsulated 3T3-L1 preadipocytes (OB[3T3]), and encapsulated 3T3Lep (OB[Lep]) in
both visceral fat pads (total 0.6106 adipocytes for each cell type). (A) Average food intake
kinetics in OB[Emp] (open circles, n = 6) and OB[Lep] (closed circles, n = 7) mice is shown as
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percent of food intake prior to injection in pre-and post-injection period. Arrow indicates the
day of injection. Asterisks show P<0.05, Student’s t-test. (B) Average weight kinetics in same
mice. Weight is shown as percent of weight prior to injection in pre-and post-injection period.
(C) Average food intake kinetics in OB[Emp] (open circles, n = 6) and OB[3T3] (closed squares,
n = 6). (D) Average weight kinetics in same mouse groups. (E) Average normalized weight of
liver to body weight in same mouse groups. All data are represented as mean ± SD. Significant
(P<0.05, Student’s t-test) statistical comparisons between groups are shown with an asterisk.
(TIF)
S2 Fig. The lack of leptin effect on intraleukin-6 (Il-6) levels in plasma and UCP1 and
PGC1α protein expression in brown adipose tissue. (A) IL-6 levels was measured in plasma
by ELISA. (n = 5 per OB[Emp] and OB[Lep]; n = 7 per OB[3T3] group). (B-D) Representative
western blot (B) and relative protein expression of PGC1α (C) and UCP1 (D) and in BAT in all
treated groups (n = 5 per OB[Emp] and OB[3T3]; n = 6 per OB[Lep] group). Data (mean ± SD)
show the ratio of PGC1α or UCP1 to β-actin.
(TIF)
S3 Fig. Leptin increases metabolic rate and raises RER. (A-D) Metabolic measurements were
performed in OB[3T3] (white bar, n = 6) and OB[Lep] (black bar, n = 6) mouse groups in
CLAMS metabolic cages at 28 days post injection. The average (mean ± SD) x, y, and z activity
(A), average VO2 (mL/kg/h) (B), respiratory exchange ratio (RER) (C), and average metabolic
rate (kcal/h/kg) (D) are shown for both the dark (D) and light (L) cycles. (E, F) Kinetic data for
RER (E) and metabolic rate (kcal/h/kg) (F) are shown as mean for each time point in OB[3T3]
(open black circles) and OB[Lep] (filled red circles) groups. (E, F) Kinetic data for RER (E) and
metabolic rate (kcal/h/kg) (F) are shown as mean for each time point in OB[3T3] (open black
circles) and OB[Lep] (filled red circles) groups.
(TIF)
S4 Fig. Leptin improves glucose tolerance. (A, B) Glucose tolerance tests (GTT) (A) or insulin
tolerance tests (ITT) (B) were performed in fasting overnight mice OB[3T3] (open circles, n = 5)
and OB[Lep] (filled circles, n = 5). Average blood glucose (mg/dL) are displayed for each time
point. Asterisks indicate significant differences P<0.05, Student’s t-test. (C) The area under the
curve (AUC) for each ITT was calculated using a trapezoidal approximation and displayed as
percent of the control OB[Emp] (n = 5) group (100%). (D). WT mice with diet-induced obesity
(Study 2) were injected with encapsulated acellular capsules (WT[Emp]) and encapsulated
3T3Lep (WT[Lep]) in both visceral fat pads (total 0.6106 adipocytes for each cell type). ITT were
performed in fasting overnight mice. Average AUC (mean ± SD) are shown for WT[Emp]
(white bar, n = 3) and WT[Lep] (black bar, n = 5).
(TIF)
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